Madison Crawford - ATAI Life Sr Accounting

ATAI Stock  USD 1.33  0.03  2.21%   

Insider

Madison Crawford is Sr Accounting of ATAI Life Sciences
Address Wallstrasse 16, Berlin, Germany, 10179
Phone49 89 2153 9035
Webhttps://www.atai.life

ATAI Life Management Efficiency

The company has return on total asset (ROA) of (0.2541) % which means that it has lost $0.2541 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6277) %, meaning that it created substantial loss on money invested by shareholders. ATAI Life's management efficiency ratios could be used to measure how well ATAI Life manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.14. The current Return On Capital Employed is estimated to decrease to -0.48. As of now, ATAI Life's Total Current Assets are increasing as compared to previous years. The ATAI Life's current Debt To Assets is estimated to increase to 0.06, while Total Assets are projected to decrease to under 261.1 M.
ATAI Life Sciences currently holds 19.14 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. ATAI Life Sciences has a current ratio of 12.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ATAI Life's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

, MBAMolecular Partners AG
51
Maurice ZaudererVaccinex
78
Theis MDGH Research PLC
48
Scott MDMind Medicine
67
Badreddin EdrisEdgewise Therapeutics
37
Seth LewisMolecular Partners AG
N/A
Behrad DerakhshanEdgewise Therapeutics
44
Annie LeeOpthea
N/A
Peter MBABio Path Holdings
75
Alan RussellEdgewise Therapeutics
54
Paul GlavineCybin Inc
35
Joanne MDIteos Therapeutics
52
Thomas SchaibleFortress Biotech
N/A
MD MBAOpthea
N/A
Leah GibsonCybin Inc
N/A
Victoria RacBio Path Holdings
N/A
Matthew MBAIteos Therapeutics
51
Magnus HalleGH Research PLC
27
Matthew GallIteos Therapeutics
47
Alan MacKenzieBio Path Holdings
N/A
MAICD MAICDOpthea
48
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany. Atai Life operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 87 people. ATAI Life Sciences (ATAI) is traded on NASDAQ Exchange in USA. It is located in Wallstrasse 16, Berlin, Germany, 10179 and employs 83 people. ATAI Life is listed under Biotechnology category by Fama And French industry classification.

Management Performance

ATAI Life Sciences Leadership Team

Elected by the shareholders, the ATAI Life's board of directors comprises two types of representatives: ATAI Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ATAI. The board's role is to monitor ATAI Life's management team and ensure that shareholders' interests are well served. ATAI Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ATAI Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ryan JD, General VP
Rolando MD, Chief Officer
Stephen Bardin, Advisor
Ryan Barrett, General VP
Michael Raven, Senior Operations
Madison Crawford, Sr Accounting
Glenn Short, Senior Development
Frank Stegert, Vice Management
Christian Angermayer, Founder Board
Florian Brand, Cofounder CEO
Anne Johnson, Chief Officer
Sahil MD, Chief Officer
Kevin MD, Senior Development
Aaqil Anwar, Mang Relations

ATAI Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ATAI Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether ATAI Life Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ATAI Life's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atai Life Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atai Life Sciences Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ATAI Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ATAI Life. If investors know ATAI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ATAI Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.97)
Earnings Share
(0.80)
Revenue Per Share
0.002
Quarterly Revenue Growth
(0.54)
Return On Assets
(0.25)
The market value of ATAI Life Sciences is measured differently than its book value, which is the value of ATAI that is recorded on the company's balance sheet. Investors also form their own opinion of ATAI Life's value that differs from its market value or its book value, called intrinsic value, which is ATAI Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ATAI Life's market value can be influenced by many factors that don't directly affect ATAI Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ATAI Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if ATAI Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ATAI Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.